---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-012186"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:41:36.738255+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta Q1 revenue $18M, net loss $33.4M; RSV data expected Q3 2024

## Summary
- Revenue $18.0M (down from $23.6M YoY) from AbbVie's MAVYRET royalties; net loss $33.4M ($1.58/share) vs $29.0M loss YoY.
- Cash and marketable securities $337.2M; expected to fund operations through fiscal 2027.
- Anticipates topline data from RSVPEDs Phase 2 study of zelicapavir and EDP-323 Phase 2a challenge study in Q3 2024.
- Expanded into immunology with oral KIT inhibitor program for chronic spontaneous urticaria; development candidate selection targeted for 2024.
- G&A expenses rose to $16.5M due to legal fees from patent infringement suit against Pfizer and higher stock compensation.

## SEC filing metadata
- accession: 0000950170-24-012186
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017024012186/0000950170-24-012186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017024012186/enta-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-012186
- JSON: https://secwatch.observer/filing/0000950170-24-012186.json
- Plain text: https://secwatch.observer/filing/0000950170-24-012186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.